Agilent Technologies Inc vs Nuscale Power Corporation — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Nuscale Power Corporation trades at $9.75 (market cap $3.77B). The key difference: Agilent Technologies Inc is far larger — about 11.1× Nuscale Power Corporation's market cap, and Agilent Technologies Inc pays a 0.69% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| A | SMR | |
|---|---|---|
Market Cap | $42.00B | $3.77B |
Sector | Health | Utilities |
52-Week High | $157.20 | $53.43 |
52-Week Low | $110.24 | $7.59 |
Enterprise Value | $43.55B | $2.70B |
Dividend Yield | 0.69% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
NuScale Power (SMR) trades at $9.83, up 3.69% with a bullish technical signal. The company reported Q2 2026 earnings that met estimates but revenues plunged 98.8% as RoPower work wound down. Despite negative profit margins and cash burn, NuScale maintains $1.9 billion liquidity and is advancing commercialization of its NRC-approved small modular reactor technology amid growing AI power demand.
The outlook hinges on successful commercial deployment of SMR technology, with potential for significant upside if large-scale projects materialize. Key risks include execution challenges, revenue volatility, and intense competition in the nuclear energy sector. Analyst consensus suggests 8% upside to the $10.63 price target, but investors should weigh the high-risk, high-reward nature of this pre-revenue growth story.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →